Skip to main content

Table 3 Risk factors for disease-free survival in stage IB NSCLC

From: Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer

  Univariate analysis Multivariate analysis (Cox hazard model)
  HR (95% CI) p value HR (95% CI) p value
Age 1.032 (1.004-1.062) 0.028 1.022 (0.994-1.051) 0.132
Sex (female vs. male) 0.795 (0.427-1.480) 0.470
ECOG   1 (vs. 0) 1.679 (0.895-3.149) 0.107 1.552 (0.802-3.002) 0.192
      2 (vs. 0) 0.802 (0.107-5.989) 0.829 0.980 (0.113-8.464) 0.985
Pneumonectomy 1.176 (0.421-3.290) 0.757
Tumor size 0.998 (0.970-1.027) 0.897
Numbers of dissected lymph nodes 0.984 (0.960-1.010) 0.207
Adenocarcinoma (vs. non-adenocarcinoma) 1.220 (0.675-2.206) 0.509
Differentiation (moderate to poor vs. well) 1.675 (0.874-3.211) 0.120
Lymphovascular invasion 0.827 (0.322-2.124) 0.692
Pleural invasion (pl2 and pl1 vs. pl0) 0.953 (0.458-1.983) 0.897
Platinum based chemotherapy (vs. no adjuvant therapy) 0.454 (0.244-0.847) 0.013 0.507 (0.263-0.978) 0.043